Federated Hermes’s Autolus Therapeutics AUTL Stock Holding History

Federated Hermes’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-78,168	Closed	-$1.03M	–	2246
2019 Q4	$1.03M	Buy	78,168 +2,617	+3%	+$34.3K	﹤0.01%	1262
2019 Q3	$938K	Buy	75,551 +21,096	+39%	+$279K	﹤0.01%	1297
2019 Q2	$877K	Buy	54,455 +5,195	+11%	+$116K	﹤0.01%	1325
2019 Q1	$1.55M	Hold	49,260	–	–	﹤0.01%	1148
2018 Q4	$1.62M	Buy	49,260 +2,313	+5%	+$76.1K	﹤0.01%	1100
2018 Q3	$1.42M	Buy	+46,947	New	+$1.27M	﹤0.01%	1236

Other funds holding AUTL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Federated Hermes's AUTL Position: Q1 2020 in Review

Federated Hermes sold out of Autolus Therapeutics (AUTL) in Q1 2020, closing a stake of 78,168 shares — an estimated $1.03M sold.

Federated Hermes first reported a position in AUTL in Q3 2018 and held it in 6 quarters. The position peaked at $1.62M in Q4 2018. 51 funds tracked by Wall St. Rank hold AUTL as of Q1 2020.

Federated Hermes reported no remaining Autolus Therapeutics position as of Q1 2020 after selling out during the quarter.
Federated Hermes sold 78,168 Autolus Therapeutics shares in Q1 2020, an estimated $1.03M.
Federated Hermes first reported a position in Autolus Therapeutics in Q3 2018 and held it in 6 quarters.
Federated Hermes's Autolus Therapeutics position peaked at $1.62M in Q4 2018.
51 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2020.

Based on Federated Hermes's 13F filing for Q1 2020, filed 13 May 2020.